Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 7;20(8):3804-3828.
doi: 10.1021/acs.molpharmaceut.3c00324. Epub 2023 Jul 21.

Rosacea Topical Treatment and Care: From Traditional to New Drug Delivery Systems

Ana Cláudia Paiva-Santos  1   2 , Tatiana Gonçalves  1 , Diana Peixoto  1   2 , Patrícia C Pires  1   2   3 , K Velsankar  4 , Niraj Kumar Jha  5   6   7   8 , Vivek P Chavda  9 , Imran Shair Mohammad  10 , Letícia Caramori Cefali  11   12 , Priscila Gava Mazzola  13 , Filipa Mascarenhas-Melo  1   2 , Francisco Veiga  1   2
Affiliations
Review

Rosacea Topical Treatment and Care: From Traditional to New Drug Delivery Systems

Ana Cláudia Paiva-Santos et al. Mol Pharm. .

Abstract

Rosacea is a multifactorial chronic inflammatory dermatosis characterized by flushing, nontransient erythema, papules and pustules, telangiectasia, and phymatous alterations accompanied by itching, burning, or stinging, the pathophysiology of which is not yet fully understood. Conventional topical treatments usually show limited efficacy due to the physical barrier property of the skin that hinders skin penetration of the active ingredients, thereby hampering proper drug skin delivery and the respective therapeutic or cosmetic effects. New advances regarding the physiopathological understanding of the disease and the underlying mechanisms suggest the potential of new active ingredients as promising therapeutic and cosmetic approaches to this dermatosis. Additionally, the development of new drug delivery systems for skin delivery, particularly the potential of nanoparticles for the topical treatment and care of rosacea, has been described. Emphasis has been placed on their reduced nanometric size, which contributes to a significant improvement in the attainment of targeted skin drug delivery. In addition to the exposition of the known pathophysiology, epidemiology, diagnosis, and preventive measures, this Review covers the topical approaches used in the control of rosacea, including skin care, cosmetics, and topical therapies, as well as the future perspectives on these strategies.

Keywords: Cosmetic; Drug Delivery System; Nanoparticle; Rosacea; Skin; Therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Summary representation of the main aspects involved in the development and manifestation of signals of rosacea (produced with Biorender).
Figure 2
Figure 2
(A) Schematization of MTZ in vitro permeation studies through pig skin. (B) Comparison of the amount of MTZ retained in the skin when applied at a dose of 1 mg through NNE and commercial gel. (C) AUC–time profiles and (D) plasma concentration of MTZ after administration via NNE and commercial gel. Adapted from Yu et al. with permission from Elsevier. Copyright 2014 Elsevier B.V.
Figure 3
Figure 3
(A) Schematic representation of the prepared ZnO nanorods, with a transmission electron microscopy image. (B) Scanning electron microscopy image of the developed cross-linked hydrogel containing ZnO nanorods. (C) Characterization of the developed transdermal system, in terms of porosity, density, and mechanical properties (tensile strength, elastic modulus, and elongation at break). Adapted from Radwan-Praglowska et al. with permission from Elsevier. Copyright 2020 The Authors.
Figure 4
Figure 4
(A) Schematic representation of the developed PGZ NNE, including performed characterization assays. (B) Tolerance study results in humans involving TEWL measurement. (C) Tolerance study results in humans involving skin hydration measurements. (D) Relative expression of inflammatory cytokines IL-6, TNF-α, and IL-1β in mice. Adapted from Espinoza et al. with permission from Elsevier. Copyright 2019 Elsevier Inc.
Figure 5
Figure 5
Efficacy end points after treatment regarding (A) inflammatory lesion count, (B) IGA end points, and (C) percent reduction in inflammatory lesions. Adapted from Gold et al. with permission from Elsevier. Copyright 2020 American Academy of Dermatology, Inc.
Figure 6
Figure 6
(A) Schematic representation of the developed hybrid lipid–polymer nanocarriers, with respective composition. (B) In vitro rat skin permeation results. (C) In vivo assay representation, with hematoxylin and eosin histological staining images. Adapted from Desai et al. with permission from Elsevier. Copyright 2013 Elsevier B.V.
Figure 7
Figure 7
Representative rosacea management scheme: nontherapeutic measures, cosmetics/skin care, topical pharmacological measures, and future challenges (produced with Biorender).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wilkin J.; Dahl M.; Detmar M.; Drake L.; Feinstein A.; Odom R.; Powell F. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J. Am. Acad. Dermatol 2002, 46 (4), 584–7. 10.1067/mjd.2002.120625. - DOI - PubMed
    1. Wilkin J.; Dahl M.; Detmar M.; Drake L.; Liang M. H.; Odom R.; Powell C. F. National Rosacea Society Expert, Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J. Am. Acad. Dermatol 2004, 50 (6), 907–912. 10.1016/j.jaad.2004.01.048. - DOI - PubMed
    1. Heisig M.; Reich A. Psychosocial aspects of rosacea with a focus on anxiety and depression. Clin Cosmet Investig Dermatol 2018, 11, 103–107. 10.2147/CCID.S126850. - DOI - PMC - PubMed
    1. Rusina T.; Snarskaya E. Erythematotelangiectatic rosacea: The combination of 0.5% brimonidine tartrate gel and broadband pulse light therapy to reverse its effects. J. Cosmet Dermatol 2021, 20 (7), 2116–2118. 10.1111/jocd.13834. - DOI - PubMed
    1. Onalaja A. A.; Lester J. C.; Taylor S. C. Establishing the diagnosis of rosacea in skin of color patients. Cutis 2019, 104 (1), 38–41. - PubMed

Substances